Microbot Medical acquires FDA-approved devices of Nitiloop

Microbot Medical has purchased the US Food and Drug Administration (FDA)-approved devices of Nitiloop for an undisclosed sum.

The acquired assets comprise the NovaCross family of microcatheters, including NovaCross CTO, NovaCross Xtreme and NovaCross BTK.

These devices enable the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions (CTO), before percutaneous transluminal coronary angioplasty (PTCA) or stent intervention.

The NovaCross microcatheter family can be used as standalone devices or incorporated into Microbot Medical’s One & Done technology. They are also anticipated to form a collection of customised procedure-related kits for the LIBERTY Robotic System.

Designed to lower capital investment requirements and Cath Lab space, the LIBERTY Robotic System is claimed to be the first-ever disposable endovascular robotic system with remote operation capabilities.

The acquisition of technologies such as the NovaCross Microcatheter family is expected to help Microbot Medical expand its market share in robotics and instruments for endovascular procedures. In the future, the company also aims to use the products to integrate imaging and big data capabilities. Medical Device Network